1. Home
  2. SCM vs PRTC Comparison

SCM vs PRTC Comparison

Compare SCM & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stellus Capital Investment Corporation

SCM

Stellus Capital Investment Corporation

HOLD

Current Price

$12.54

Market Cap

397.8M

Sector

Finance

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$16.76

Market Cap

386.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCM
PRTC
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.8M
386.7M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
SCM
PRTC
Price
$12.54
$16.76
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$13.00
N/A
AVG Volume (30 Days)
158.5K
2.2K
Earning Date
11-10-2025
08-28-2025
Dividend Yield
12.80%
N/A
EPS Growth
N/A
N/A
EPS
1.09
0.20
Revenue
$102,538,895.00
$6,391,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$11.44
$8.13
Revenue Growth
N/A
1265.60
52 Week Low
$11.19
$13.30
52 Week High
$15.56
$20.00

Technical Indicators

Market Signals
Indicator
SCM
PRTC
Relative Strength Index (RSI) 51.23 49.31
Support Level $12.55 $16.75
Resistance Level $12.85 $17.85
Average True Range (ATR) 0.25 0.46
MACD -0.02 0.06
Stochastic Oscillator 21.76 40.48

Price Performance

Historical Comparison
SCM
PRTC

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: